APA (7th ed.) Citation

MFJM, V., JAAC, H., GJ, G., J, O. N., PP, D. D., S, H., . . . C, H. (2022). Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. Clinical and translational science, 15(8), 2010. https://doi.org/10.1111/cts.13317

Chicago Style (17th ed.) Citation

MFJM, Vissers, et al. "Safety, Pharmacokinetics and Target Engagement of Novel RIPK1 Inhibitor SAR443060 (DNL747) for Neurodegenerative Disorders: Randomized, Placebo-controlled, Double-blind Phase I/Ib Studies in Healthy Subjects and Patients." Clinical and Translational Science 15, no. 8 (2022): 2010. https://doi.org/10.1111/cts.13317.

MLA (9th ed.) Citation

MFJM, Vissers, et al. "Safety, Pharmacokinetics and Target Engagement of Novel RIPK1 Inhibitor SAR443060 (DNL747) for Neurodegenerative Disorders: Randomized, Placebo-controlled, Double-blind Phase I/Ib Studies in Healthy Subjects and Patients." Clinical and Translational Science, vol. 15, no. 8, 2022, p. 2010, https://doi.org/10.1111/cts.13317.